This pattern is consistent with the frequencies of TP53 mutations in 5–10 percent of people with de novo myelodysplastic neoplasms (MDS) versus 30–40 percent of those with MDS or AML proposed to be therapy-related [20]. This evidence concerns the gene TP53 and myelodysplastic syndrome.